PAREXEL TO ADDRESS PROVEN APPROACHES TO REALIZE SIGNIFICANT VALUE AT PARTNERSHIPS IN CLINICAL TRIALS CONFERENCE
Boston, MA, February 22, 2012—Experts from PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, will address proven approaches to derive significant value from strategic partnerships during the 21st Annual Partnerships in Clinical Trials conference, to be held March 4-7, 2012 in Orlando, Florida. By visiting the PAREXEL Booth #824 in the exhibit hall, attendees will have the opportunity to learn more about how PAREXEL works collaboratively with clients to deliver higher levels of cost reductions and time savings through these longer-term relationships. PAREXEL experts will also discuss how several types of partnership models, for companies of all sizes, can be tailored to meet their specific needs and goals.
PAREXEL has been an innovator in creating strategic partnerships in the biopharmaceutical services industry for 30 years. PAREXEL’s advanced approach to strategic partnering focuses on assisting biopharmaceutical companies in reducing fixed costs, shortening development times, and speeding delivery of safe and effective treatments to market. PAREXEL has transformed its business to deliver a new level of strategic partnering, based on program design expertise, operational excellence, and project leadership to help clients achieve their development and commercialization goals.
The conference program features the following sessions presented by PAREXEL experts, with a focus on innovative and collaborative approaches to achieve greater efficiency and effectiveness in drug development and commercialization:
Innovative Patient Recruitment and Patient Strategies Track, March 5, 1:30 p.m.: Case Study: Use EMR and Social Media to Bolster Patient Recruitment for Post-Marketing Trials—Ramita Tandon, Global Head of Late Phase Clinical Trials, PAREXEL
Virtual Clinical Trials Track, March 5, 2:15 p.m.: Examine Collaboration of Technology Companies Needed to Support the Virtual Trial Model—Michelle Carnevale, Associate Director, Client Services, Perceptive Informatics
Strategic Outsourcing Track, March 6, 4:00 p.m.: Case Study: Setting Up a Working Collaboration Across Three Strategic Partners—Mario Papillon, Vice President, Strategic Account Leader, PAREXEL
PAREXEL provides the breadth and depth of expertise to create customized development and commercialization solutions that fit the client—whether an emerging research venture, a growing mid-size business, or a global enterprise. PAREXEL’s clients benefit from proven best practices and quality standards to bolster the success of their development efforts. PAREXEL delivers a spectrum of outsourcing models that help biopharmaceutical companies accomplish their goals at every stage of clinical development.
For more information about how PAREXEL helps biopharmaceutical companies improve development effectiveness and operating efficiency through strategic partnership models visit: http://www.parexel.com/business-challenges/strategic-partnering/ or Booth #824 during the conference.
Information about Partnerships in Clinical Trials can be found at www.clinicaltrialpartnerships.com.
# # #
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 11,300 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated additional restructuring charges of approximately $2.0 million in the third quarter of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2011 as filed with the SEC on November 9, 2011, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.